Stereotaxis

STXS · NYSE American

$0.9983−$0.0117 (−1.16%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $1.01

STXS analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $3.06 (+206.5% upside)

Low: $3.03
Now: $0.9983
High: $3.15

Upgrades and downgrades

The latest rating actions, newest first

STXS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citizens	Aug 27, 2026	Maintains	Market Outperform	$4.00 → $3.00	36%
TD Cowen	Aug 12, 2026	Maintains	Buy	$5.00 → $3.00	48%
Piper Sandler	May 13, 2026	Maintains	Overweight	$4.00 → $3.50	51%
Citizens	Dec 16, 2025	Initiates	Market Outperform	$4.00	36%
Roth Capital	Nov 12, 2025	Maintains	Buy	$4.00	48%
Roth Capital	Nov 5, 2025	Initiates	Buy	$4.00	48%

The case for and against

Updated Oct 16, 2026

Bull case

Stereotaxis is attractive because its core disposable and robotic ecosystem is beginning to translate regulatory wins into recurring revenue growth, with 2Q26 recurring revenue of $6.2 million up 7.5% year over year and catheter sales topping $1 million. The company now has multiple commercial catalysts, including GenesisX, MAGiC ablation, and Synchrony approvals, while management expects cash-flow profitability in 1H27 and sees relatively modest assumptions needed to reach break-even. Although 2Q26 system placements were pressured and manufacturing constraints remain a hurdle, the early traction in new products, expected sequential improvement in 3Q and 4Q, and a 2027 revenue estimate near $47 million support a constructive long-term outlook.

Bear case

Stereotaxis is facing a weak fundamental setup because its revenue base remains uneven, with system sales highly volatile and recurring revenue not yet strong enough to offset periodic shortfalls. Q1 revenue of $6.3M and Q2 revenue of $7.7M both missed expectations, while system revenue fell 32.8% and 51% year over year in those periods, highlighting dependence on lumpy capital equipment purchases and slow adoption cycles. The bearish view is reinforced by ongoing cash flow and financing risk, elevated operating expenses near $9M per quarter, and lowered 2027 sales estimates to $47.0M from $53.0M amid supply constraints, competitive pressure, and execution uncertainty.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.